Biofrontera Inc. (BFRI) (Seite 3)
eröffnet am 29.12.21 23:35:38 von
neuester Beitrag 02.02.24 16:38:08 von
neuester Beitrag 02.02.24 16:38:08 von
Beiträge: 30
ID: 1.355.960
ID: 1.355.960
Aufrufe heute: 2
Gesamt: 4.535
Gesamt: 4.535
Aktive User: 0
ISIN: US09077D1000 · WKN: A3C6YA
0,5400
USD
+3,85 %
+0,0200 USD
Letzter Kurs 03.07.23 Nasdaq
Neuigkeiten
| TitelBeiträge |
|---|
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2554 | +9.943,20 | |
| 7,9600 | +151,90 | |
| 2,3900 | +32,04 | |
| 6,7800 | +30,13 | |
| 3,1100 | +29,05 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 7,4800 | -17,80 | |
| 9,6000 | -18,64 | |
| 8,6850 | -20,47 | |
| 2,0400 | -58,87 | |
| 0,8020 | -91,06 |
Beitrag zu dieser Diskussion schreiben
Feedback
Was ist der Unterschied zwischen "catching falling knife" und "bottom fishing"? 
Einfaches Einfügen von wallstreetONLINE Charts: So funktionierts.
Antwort auf Beitrag Nr.: 71.583.969 von faultcode am 16.05.22 14:02:58https://api.quotemedia.com/supplement/news-story/?webmasterI…
...
...
...
...
Antwort auf Beitrag Nr.: 71.571.882 von faultcode am 13.05.22 16:18:37https://api.quotemedia.com/supplement/news-story/?webmasterI…
Antwort auf Beitrag Nr.: 71.353.474 von faultcode am 13.04.22 19:33:22
...
https://api.quotemedia.com/supplement/news-story/?webmasterI…
...
https://api.quotemedia.com/supplement/news-story/?webmasterI…
https://api.quotemedia.com/supplement/news-story/?webmasterI…
Biofrontera Inc. Announces FDA Approval of Biofrontera Pharma GmbH as a Contract Laboratory for Ameluz®
Significantly Improves Manufacturing Efficiency , Quality Control and Supply Reliability
WOBURN, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the U.S. Food and Drug Administration (FDA) has approved Biofrontera Pharma’s cGMP laboratory in Leverkusen, Germany, as a contract laboratory for batch control and stability testing of Ameluz ® (aminolevulinic acid hydrochloride gel, 10%). This recognition enables significant improvements in product manufacturing efficiency, quality control and reliability of supply.
The FDA cleared Biofrontera Pharma GmbH’s laboratory to operate a method of impurity testing, which is a critical component of the gel’s stability assurance. The clearance enables part of the necessary testing of production batches to be performed in the Leverkusen facility, thereby reducing dependence on third-party suppliers and the risk of production downtime and product delays. Previously, quality control was conducted entirely by contract manufacturers in collaboration with third-party providers.
“Impurity testing is extremely complex and one of the most important components of batch release and stability testing. To establish such a method at third-party suppliers could take a year or two, and several contract laboratories have already failed at establishing the specific methods we need for Ameluz ® . Bringing this important function under the control of our licensor therefore strengthens quality control, reduces third-party dependence and enables transparency to identify opportunities for further developments,” stated Hermann Lübbert, Executive Chairman of Biofrontera Inc.
“Under a license and supply agreement with Biofrontera AG, we have exclusive rights to market and sell Ameluz and the PDT-lamps BF-RhodoLED ® and RhodoLED XL in the U.S. As our U.S. commercial sales build momentum, we appreciate the importance of optimizing for scale and ensuring commercial supply without compromising quality,” stated Erica Monaco, Chief Executive Officer of Biofrontera Inc.
...
=>
Biofrontera Inc. Announces FDA Approval of Biofrontera Pharma GmbH as a Contract Laboratory for Ameluz®
Significantly Improves Manufacturing Efficiency , Quality Control and Supply Reliability
WOBURN, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the U.S. Food and Drug Administration (FDA) has approved Biofrontera Pharma’s cGMP laboratory in Leverkusen, Germany, as a contract laboratory for batch control and stability testing of Ameluz ® (aminolevulinic acid hydrochloride gel, 10%). This recognition enables significant improvements in product manufacturing efficiency, quality control and reliability of supply.
The FDA cleared Biofrontera Pharma GmbH’s laboratory to operate a method of impurity testing, which is a critical component of the gel’s stability assurance. The clearance enables part of the necessary testing of production batches to be performed in the Leverkusen facility, thereby reducing dependence on third-party suppliers and the risk of production downtime and product delays. Previously, quality control was conducted entirely by contract manufacturers in collaboration with third-party providers.
“Impurity testing is extremely complex and one of the most important components of batch release and stability testing. To establish such a method at third-party suppliers could take a year or two, and several contract laboratories have already failed at establishing the specific methods we need for Ameluz ® . Bringing this important function under the control of our licensor therefore strengthens quality control, reduces third-party dependence and enables transparency to identify opportunities for further developments,” stated Hermann Lübbert, Executive Chairman of Biofrontera Inc.
“Under a license and supply agreement with Biofrontera AG, we have exclusive rights to market and sell Ameluz and the PDT-lamps BF-RhodoLED ® and RhodoLED XL in the U.S. As our U.S. commercial sales build momentum, we appreciate the importance of optimizing for scale and ensuring commercial supply without compromising quality,” stated Erica Monaco, Chief Executive Officer of Biofrontera Inc.
...
=>
Trading Spotlight
8.4.
Biofrontera Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update
https://api.quotemedia.com/supplement/news-story/?webmasterI…
...
Financial Guidance
Biofrontera today introduced financial guidance for 2022, as follows:
• Total revenues are expected to increase by at least 30% compared with 2021, including first quarter total revenues up by over 100% versus the first quarter prior year and typical seasonal strength in the first and fourth quarters
• The commercial focus throughout 2022 will be on achieving deeper sales penetration among current customer accounts, with additions to the Biofrontera sales force expected to begin in 2023
...
Biofrontera Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update
https://api.quotemedia.com/supplement/news-story/?webmasterI…
...
Financial Guidance
Biofrontera today introduced financial guidance for 2022, as follows:
• Total revenues are expected to increase by at least 30% compared with 2021, including first quarter total revenues up by over 100% versus the first quarter prior year and typical seasonal strength in the first and fourth quarters
• The commercial focus throughout 2022 will be on achieving deeper sales penetration among current customer accounts, with additions to the Biofrontera sales force expected to begin in 2023
...
Antwort auf Beitrag Nr.: 71.295.462 von faultcode am 06.04.22 14:44:11
seid ihr alle bei der Party dabei oder klemmt ihr noch in DE0006046113 fest?
seid ihr alle bei der Party dabei oder klemmt ihr noch in DE0006046113 fest?
Antwort auf Beitrag Nr.: 71.258.328 von faultcode am 01.04.22 19:05:11https://api.quotemedia.com/supplement/news-story/?webmasterI…
...
...
Biofrontera Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on April 8, 2022
WOBURN, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today it will report financial results for the three months and full year ended December 31, 2021 before the opening of the U.S. financial markets on Friday, April 8, 2022 and will host a conference call that same day beginning at 11:00 a.m. Eastern time to discuss those results, provide a business update and answer questions.
...
https://api.quotemedia.com/supplement/news-story/?webmasterI…
WOBURN, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today it will report financial results for the three months and full year ended December 31, 2021 before the opening of the U.S. financial markets on Friday, April 8, 2022 and will host a conference call that same day beginning at 11:00 a.m. Eastern time to discuss those results, provide a business update and answer questions.
...
https://api.quotemedia.com/supplement/news-story/?webmasterI…
Biofrontera Inc. -- eine der lustigsten Aktien im Nasdaq Capital Market (NasdaqCM)
Tagesbewegungen von +98% bis -30% in 24 Stunden
Tagesbewegungen von +98% bis -30% in 24 Stunden
Durchsuchen
